Castle Biosciences, Inc. (CSTL)
CSTL Stock Price Chart
Explore Castle Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze CSTL price movements and trends.
CSTL Company Profile
Discover essential business fundamentals and corporate details for Castle Biosciences, Inc. (CSTL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
25 Jul 2019
Employees
784.00
Website
https://castlebiosciences.comCEO
Derek J. Maetzold
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
CSTL Financial Timeline
Browse a chronological timeline of Castle Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 3 Nov 2025
EPS estimate is -$0.35, while revenue estimate is $71.21M.
Earnings released on 4 Aug 2025
EPS came in at $0.15 surpassing the estimated -$0.51 by +129.41%, while revenue for the quarter reached $86.19M , beating expectations by +26.75%.
Earnings released on 5 May 2025
EPS came in at -$0.20 falling short of the estimated -$0.08 by -150.00%, while revenue for the quarter reached $87.99M , beating expectations by +22.51%.
Earnings released on 27 Feb 2025
EPS came in at $0.32 surpassing the estimated -$0.04 by +900.00%, while revenue for the quarter reached $86.31M , beating expectations by +2.89%.
Earnings released on 4 Nov 2024
EPS came in at $0.08 surpassing the estimated -$0.06 by +233.33%, while revenue for the quarter reached $85.78M , beating expectations by +6.46%.
Earnings released on 5 Aug 2024
EPS came in at $0.31 surpassing the estimated -$0.27 by +214.81%, while revenue for the quarter reached $87.00M , beating expectations by +25.47%.
Earnings released on 2 May 2024
EPS came in at -$0.09 surpassing the estimated -$0.37 by +75.68%, while revenue for the quarter reached $72.97M , beating expectations by +10.23%.
Earnings released on 28 Feb 2024
EPS came in at -$0.10 surpassing the estimated -$0.84 by +88.10%, while revenue for the quarter reached $66.12M , beating expectations by +17.48%.
Earnings released on 2 Nov 2023
EPS came in at -$0.26 surpassing the estimated -$0.92 by +71.74%, while revenue for the quarter reached $61.49M , beating expectations by +21.34%.
Earnings released on 2 Aug 2023
EPS came in at -$0.70 surpassing the estimated -$1.01 by +30.69%, while revenue for the quarter reached $50.14M , beating expectations by +13.46%.
Earnings released on 3 May 2023
EPS came in at -$1.10 falling short of the estimated -$0.80 by -37.50%, while revenue for the quarter reached $42.04M , missing expectations by -1.16%.
Earnings released on 28 Feb 2023
EPS came in at -$0.78 surpassing the estimated -$0.91 by +14.29%, while revenue for the quarter reached $38.34M , beating expectations by +3.29%.
Earnings released on 2 Nov 2022
EPS came in at -$0.77 falling short of the estimated -$0.70 by -10.00%, while revenue for the quarter reached $37.01M , beating expectations by +6.49%.
Earnings released on 8 Aug 2022
EPS came in at -$0.06 surpassing the estimated -$0.58 by +89.66%, while revenue for the quarter reached $34.84M , beating expectations by +22.80%.
Earnings released on 9 May 2022
EPS came in at -$0.80 falling short of the estimated -$0.67 by -19.40%, while revenue for the quarter reached $26.85M , beating expectations by +6.42%.
Earnings released on 28 Feb 2022
EPS came in at -$0.25 surpassing the estimated -$0.43 by +41.86%, while revenue for the quarter reached $25.04M , beating expectations by +5.48%.
Earnings released on 8 Nov 2021
EPS came in at -$0.47 falling short of the estimated -$0.35 by -34.29%, while revenue for the quarter reached $23.48M , missing expectations by -0.74%.
Earnings released on 9 Aug 2021
EPS came in at -$0.34 falling short of the estimated -$0.29 by -17.24%, while revenue for the quarter reached $22.76M , beating expectations by +20.29%.
Earnings released on 10 May 2021
EPS came in at -$0.17 surpassing the estimated -$0.22 by +22.73%, while revenue for the quarter reached $22.81M , missing expectations by -20.69%.
Earnings released on 8 Mar 2021
EPS came in at -$0.16 falling short of the estimated -$0.11 by -45.45%, while revenue for the quarter reached $17.30M .
Earnings released on 9 Nov 2020
EPS came in at -$0.23 falling short of the estimated -$0.06 by -283.33%, while revenue for the quarter reached $15.22M , beating expectations by +31.69%.
CSTL Stock Performance
Access detailed CSTL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.